Frank Rimerman Advisors LLC Acquires 2,478 Shares of Becton, Dickinson and Company (NYSE:BDX)

Frank Rimerman Advisors LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6,043.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,519 shares of the medical instruments supplier’s stock after buying an additional 2,478 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Becton, Dickinson and Company were worth $589,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. WR Wealth Planners LLC increased its stake in shares of Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC boosted its position in shares of Becton, Dickinson and Company by 1.5% in the 1st quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after purchasing an additional 43 shares in the last quarter. Key Client Fiduciary Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 2.6% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 43 shares during the last quarter. Clear Creek Financial Management LLC increased its position in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares in the last quarter. Finally, Edge Capital Group LLC raised its stake in Becton, Dickinson and Company by 3.1% during the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after buying an additional 48 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent analyst reports. Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup lowered their price objective on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Trading Up 0.5 %

Shares of Becton, Dickinson and Company stock opened at $234.70 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The company has a market capitalization of $67.83 billion, a P/E ratio of 51.70, a P/E/G ratio of 1.91 and a beta of 0.42. The company has a fifty day moving average of $235.68 and a 200 day moving average of $235.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter last year, the company earned $2.96 EPS. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.